Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 04 August 2017
Indication(s)
- Treatment of invasive candidiasis in adult or paediatric patients.
- Treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and/or itraconazole.
Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.
- Empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropaenic adult or paediatric patients.
Learning Zones
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
Hyperammonaemia
Hyperammonaemia can result in serious neurological damage or death. Could you recognise the signs and symptoms?
+ 2 more
Pain, Agitation and Delirium (PAD) Management
Discover the latest guidance on assessment and management of pain, agitation and delirium for patients requiring sedation.
+ 4 more
Fluid Management
Are you up-to-date with the latest evidence of effective procedures for fluid management?
+ 2 more
Breakthrough Cancer Pain Learning Zone
Watch video highlights from the BeCOn OWN 2017 event, including expert opinion, patient experience and panel discussions in the Breakthrough Cancer Pain Learning Zone.
Oral Anticoagulation Reversal
Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.
Hunter Syndrome
Hunter syndrome (MPS II) has symptoms which overlap with many common childhood complaints – do you know what to look for?
Cushing's Syndrome
Cushing’s syndrome shares symptoms such as hypertension, glucose intolerance and obesity with other common conditions – how can you confidently diagnose this rare disorder?
+ 2 more
Related Content
Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)
This study aims to compare treatment with imipenem/relebactam/cilastatin (IMI/REL) as a fixed-dose combination (FDC) with piperacillin/tazobactam (PIP/TAZ) FDC in participants...
Added 3 years ago
Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium + Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)
The study will evaluate the efficacy and safety of imipenem+cilastatin/relebactam (MK-7655A) versus colistimethate sodium + imipenem+cilastatin in the treatment of...
Added 3 years ago
Pharmacokinetics of Once Daily Darunavir/Ritonavir in HIV-infected Children (DAPHNE)
Darunavir/ritonavir is one of the preferred antiretroviral agents as part of combination antiretroviral therapy for treatment of HIV-infected adults according...
Added 4 years ago
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination in Adolescents and Children With Chronic HCV-Infection
This study will have two parts as follows: The PK Lead-in Phase of the study will evaluate the steady state...
Added 4 years ago
A Study in Belgian Children Hospitalized With Respiratory Syncytial Virus Related Acute Respiratory Infections
The purpose of the study is to assess viral kinetics and clinical symptoms kinetics in pediatric patients hospitalized with Respiratory...
Added 4 years ago
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.
Background: Mucormycosis is an uncommon invasive fungal disease with high mortality and few treatment options. Isavuconazole is a triazole active...
Added 2 years ago
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial
Background: Isavuconazole is a novel triazole with broad-spectrum antifungal activity. The SECURE trial assessed efficacy and safety of isavuconazole versus...
Added 2 years ago
Postantifungal Effect of Micafungin against the Species Complexes of Candida albicans and Candida parapsilosis.
Micafungin is an effective antifungal agent useful for the therapy of invasive candidiasis. Candida albicans is the most common cause...
Added 2 years ago
ESCMID guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.
Invasive candidiasis (IC) is a relatively common syndrome in neonates and children and is associated with significant morbidity and mortality....
Added 5 years ago
British Association of Dermatologists’ guidelines for the management of tinea capitis 2014
The overall objective of this guideline is to provide up-todate, evidence-based recommendations for the management of tinea capitis.
Added 3 years ago
ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others
The overall aim of this guidance is to address the difficulties in managing and diagnosing invasive fungal infections due to...
Added 4 years ago
More information
Category | Value |
---|---|
Agency product number | EMEA/H/C/000379 |
Orphan designation | No |
Date First Approved | 24-10-2001 |
Type | POM |
Marketing authorisation holder | Merck Sharp & Dohme Ltd. |